News - Boehringer Ingelheim

Filter

Current filters:

Boehringer Ingelheim

Popular Filters

154 to 167 of 167 results

AIDS drugmakers’ charity programs fail patients, yet provide millions in tax breaks to industry, AHF accuses, but applauds Boehringer

03-08-2011

The USA-based AIDS Healthcare Foundation (AHF) is, in its own words, “blowing the whistle”…

Boehringer IngelheimFinancialGilead SciencesNorth AmericaPharmaceuticalPricing

Now Boehringer and Bristol-Myers in talks to join Medicines Patent Pool for HIV medicines

19-07-2011

Following swiftly on its first deal with a pharmaceutical company, the Medicines Patent Pool, which was…

Anti-viralsBoehringer IngelheimBristol-Myers SquibbGlobalPatentsPharmaceutical

EU Commission closes antitrust case in Boehringer/Almirall dispute over COPD drugs

07-07-2011

The European Commission has closed an antitrust investigation into allegations by Spain’s largest…

AlmirallBoehringer IngelheimEuropeLegalPatentsPharmaceuticalRespiratory and PulmonarySpiriva

Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial

24-06-2011

US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPradaxaResearchXarelto

Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal

17-06-2011

German independent drug major Boehringer Ingelheim has signed an exclusive global licence and collaboration…

Boehringer IngelheimDiabetesLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Boehringer Ingelheim and Lilly begin US roll-out of diabetes drug Tradjenta

16-06-2011

German independent drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) announced yesterday…

Boehringer IngelheimDiabetesEli LillyMarkets & MarketingNorth AmericaPharmaceuticalTradjenta

Judge vacates Amylin injunction against Eli Lilly; latter updates Humalog label

09-06-2011

It was a good news day for US drug major Eli Lilly (NYSE: LLY) yesterday, as the firm received approval…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionHumalogLegallinagliptinNorth AmericaPharmaceuticalRegulation

Investment in oncology drug development remains strong, with 133 firm initiating late-stage trials

03-06-2011

Trials targeting non-small cell lung cancer, breast cancer and multiple hematological cancers are amongst…

Boehringer IngelheimMerck KGaANovartisOncologyPharmaceuticalResearchRoche

Changing the Indian culture in reporting adverse drug reactions

01-06-2011

Adverse drug reactions (ADRs) are the sixth global leading cause of death among hospitalized patients…

Asia-PacificBoehringer IngelheimPharmaceuticalRegulationResearch

Amylin wins first round in squabble with Lilly over diabetes link with Boehringer

27-05-2011

In an initial win for US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), the US District Court for…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionLegallinagliptinNorth AmericaPharmaceuticalTradjenta

Amylin sues Eli Lilly, alleging anti-competitive activity

17-05-2011

San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

US FDA clears Boehringer and Lilly’s diabetes drug Tradjenta

04-05-2011

The US Food and Drug Administration has approved Tradjenta (linagliptin), for use along with diet and…

Boehringer IngelheimDiabetesEli LillylinagliptinNorth AmericaPharmaceuticalRegulationTradjenta

154 to 167 of 167 results

Back to top